Clinical trials: Ulcerative Colitis (Disorder)
Colitis, Ulcerative
This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients
The primary objective of this trial is to understand the mechanism of action of BI655130 in patients with UC Secondary objectives are to explore clinical effect, safety and tolerability (including immunogenicity) of BI 655130…
- Trial name
- NCT03100864
- Testing
- Spesolimab
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 8 people
- Sponsor
- Boehringer Ingelheim
Ulcerative Colitis
A Comparison of Once a Day Dose Compared to 2 Doses/Day
The purpose of this study is to compare the efficacy in maintaining remission of ulcerative colitis between a once daily (QD) Asacol regimen and a divided, twice daily (BID) Asacol dosing regimen.
- Trial name
- NCT00505778
- Testing
- Mesalamine Once-Daily, Mesalamine Twice-Daily
- Where
- 245 sites in United States, Canada and 1 more
- Volunteers
- 1,027 people
- Sponsor
- Warner Chilcott
Colonic Cancer, Rectal Cancer
Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection
Laparoscopic (key-hole) large bowel resection is a minimally invasive procedure when compared to open large bowel resection, but is still associated with a significant amount of pain and discomfort.
- Conditions
- Colonic Cancer, Rectal Cancer, Colonic Diverticulum, Ulcerative Colitis
- Trial name
- NCT01339273
- Testing
- Ultrasound guided Transversus Abdominis Plane (TAP) bock, Local anaesthetic infiltration of laparoscopic port sites
- Where
- United Kingdom
- Volunteers
- 72 people
- Sponsor
- Oxford University Hospitals NHS Trust
Ulcerative Colitis
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
To assess the long-term safety and maintenance of response of adalimumab in subjects with ulcerative colitis who participated in and successfully completed M06-826 (NCT00385736) or M06-827 (NCT00408629).
- Trial name
- NCT00573794
- Testing
- adalimumab
- Volunteers
- 592 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ulcerative Colitis
Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis
This study is a prospective clinical study to evaluate the safety and efficacy of two different doses of Asacol for the treatment of moderately active ulcerative colitis.
- Trial name
- NCT00073021
- Testing
- Asacol 800 mg (mesalamine), Asacol 400 mg (mesalamine)
- Where
- 57 sites in United States, Canada and 1 more
- Volunteers
- 386 people
- Sponsor
- Warner Chilcott
Ulcerative Colitis (UC)
Efficacy & Safety of TD-1473 in Ulcerative Colitis
A Phase 2b/3 set of studies to evaluate the efficacy and safety of induction and maintenance therapy with TD-1473 in subjects with moderately-to-severely active ulcerative colitis with up to 60 weeks of treatment.
- Trial name
- RHEA (NCT03758443)
- Testing
- TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C
- Where
- 188 sites in United States, Australia and 20 more
- Volunteers
- 239 people
- Sponsor
- Theravance Biopharma
Ulcerative Colitis
Use of Rectal Dialysis Technique to Measure Rectal 5-ASA Levels in Healthy Volunteers Receiving Asacol
The investigators plan to develop a novel method of estimating 5-ASA levels in the rectum at a mucosal level using in vivo rectal dialysis technique towards the eventual goal of determining the optimal dosing of Asacol® that…
- Trial name
- NCT04032652
- Testing
- Rectal dialysis
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Endeavor Health
Colitis, Ulcerative
A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis
MultiStem(r) is a new biological product, manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources.
- Trial name
- NCT01240915
- Testing
- MultiStem low dose, MultiStem high dose
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 105 people
- Sponsor
- Pfizer
Ulcerative Colitis
Efficacy and Safety of Oral BT-11 in Ulcerative Colitis
This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter study with an optional open-label extension (OLE) period.
- Trial name
- NCT03861143
- Testing
- BT-11 (440 mg), BT-11 (880 mg)
- Where
- 16 sites in United States, Bosnia and Herzegovina and 3 more
- Volunteers
- 198 people
- Sponsor
- NImmune Biopharma
Colitis, Ulcerative, Crohn's Disease
A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
The main aim of the study is to check for long-term side effects of Vedolizumab Subcutaneous (also known as Vedolizumab SC) in people with ulcerative colitis (UC) and Crohn's disease (CD).
- Trial name
- NCT02620046
- Testing
- Vedolizumab SC
- Where
- 301 sites in United States, Argentina and 31 more
- Volunteers
- 746 people
- Sponsor
- Takeda
Venous Thromboses, Venous Thromboembolism
The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
Blood clots occurring in the legs and in the lungs are relatively common; they occur in around 3 in a 1000 people per year. They can cause disability and are also potentially life threatening.
- Conditions
- Venous Thromboses, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT03835780
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 266,890 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Colitis, Ulcerative
A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy
The objectives of this trial are safety and efficacy (proof-of-concept) of induction of mucosal healing by BI 655130 add-on therapy in patients with mild or moderate ulcerative colitis and persisting endoscopic activity despite…
- Trial name
- NCT03123120
- Testing
- Spesolimab
- Where
- 16 sites in Denmark, Germany and 4 more
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Ulcerative Colitis
Long-Term Safety Of PF-00547659 In Ulcerative Colitis
Subjects with Ulcerative Colitis who have completed an induction study with PF-00547659 will receive an additional 144 weeks of open-label treatment to evaluate the long-term safety of the drug.
- Trial name
- TURANDOT II (NCT01771809)
- Testing
- 75mg SHP647 (PF-00547659), 225mg SHP647 (PF-00547659)
- Where
- 99 sites in United States, Australia and 19 more
- Volunteers
- 330 people
- Sponsor
- Shire
Ulcerative Colitis
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis
The primary objectives of this study are as follows: To assess the safety and tolerability of escalating single and multiple doses of GS-5745 (andecaliximab) in participants with moderate to severe ulcerative colitis (UC) as…
- Trial name
- NCT01831427
- Testing
- Andecaliximab
- Where
- 16 sites in United States, Belgium and 5 more
- Volunteers
- 74 people
- Sponsor
- Gilead Sciences
Ulcerative Colitis
Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
The purpose of this study is to determine whether RPC1063 is effective in the treatment of Ulcerative Colitis (UC).
- Trial name
- NCT02435992
- Testing
- RPC1063
- Where
- 372 sites in United States, Argentina and 28 more
- Volunteers
- 1,012 people
- Sponsor
- Celgene
Ulcerative Colitis
A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis
The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in children with moderately to severely active ulcerative colitis.
- Trial name
- NCT00336492
- Testing
- infliximab
- Where
- 27 sites in United States, Belgium and 3 more
- Volunteers
- 60 people
- Sponsor
- Centocor, Inc.
Ulcerative Colitis, Healthy
GI Permeability Change in Response to Aquamin®
This trial is being completed to learn about how Aquamin® affects gastrointestinal permeability, or the control of material passing from inside the gastrointestinal tract through the gut wall into the rest of the body, in people…
- Conditions
- Ulcerative Colitis, Healthy, Irritable Bowel Syndrome With Diarrhea
- Trial name
- NCT04855799
- Testing
- Aquamin
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- James Varani
Crohn Disease, Ulcerative Colitis
Autoimmune Protocol Diet and Inflammatory Bowel Disease
There is limited data to guide the use of dietary change in the management of IBD, and it can prove challenging to implement in the setting of altered anatomy, comorbid conditions, and patient compliance.
- Conditions
- Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
- Trial name
- NCT03512327
- Testing
- Autoimmune protocol (AIP) diet
- Volunteers
- 15 people
- Sponsor
- Scripps Health
Ulcerative Colitis, Digestive System Diseases
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
The purpose of this study is to determine the safety and tolerability of administration of multiple ascending doses of KHK4083 and to select the highest dose tolerated by subjects with moderately active Ulcerative Colitis (UC)…
- Conditions
- Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative, Colitis
- Trial name
- NCT02647866
- Testing
- KHK4083
- Where
- 23 sites in United States, Czechia and 5 more
- Volunteers
- 66 people
- Sponsor
- Kyowa Kirin, Inc.
Ulcerative Colitis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of…
- Trial name
- NCT06137183
- Testing
- Vixarelimab
- Where
- 65 sites in United States, Brazil and 10 more
- Volunteers
- 79 people
- Sponsor
- Genentech, Inc.